ClinConnect ClinConnect Logo
Search / Trial NCT06401993

Peripheral-central Correlation Study on the Treatment of Chronic Tinnitus With "Dao qi Tong Luo" Based on the Theory of "Connecting the Two Ears to the Brain"

Launched by THE THIRD AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY · May 3, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Acupuncture Fnirs Tinnitus Abr

ClinConnect Summary

This clinical trial is investigating a treatment for chronic tinnitus, a condition where individuals hear ringing or buzzing in their ears that can be very bothersome. The study aims to understand how this condition relates to brain activity and blood flow by comparing people with tinnitus to healthy individuals. Researchers will also explore the effects of a specific treatment called "Dao qi Tong Luo" on tinnitus symptoms and the underlying mechanisms that may help improve the condition.

To participate in this trial, you need to be between 20 and 55 years old, experience chronic tinnitus for at least six months, and have normal hearing. Healthy participants without any ear issues are also needed for comparison. Throughout the study, participants will undergo various tests to monitor their symptoms and brain activity. If you're considering joining, it’s important to note that there are specific health criteria that could exclude you, such as a history of serious medical conditions or certain ear disorders. This trial is currently recruiting participants, and it offers a chance to contribute to understanding and potentially improving treatment for tinnitus.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Inclusion criteria for patients with chronic tinnitus
  • 1. Chronic tinnitus patients, that is, the course of disease ≥6 months;
  • 2. No contraindications of fNIRS scanning;
  • 3. The age of 20 years ≤55 years old, gender is not limited, right-handed;
  • 4. The external ear canal is unobstructed and the eardrum is intact
  • 5. The average hearing threshold of both ears is \<35dB;
  • 6. Normal expression and understanding ability. Inclusion criteria for healthy subjects
  • <!-- -->
  • 1. No tinnitus, no hearing disorders and other ear diseases;
  • 2. Good health condition, no history of mental disease and nervous system disease;
  • 3. No contraindications of fNIRS scanning;
  • 4. The age of 20 years ≤55 years old, gender is not limited, right-handed;
  • 5. The external ear canal is unobstructed, and the tympanic membrane is complete;
  • 6. Normal expression and understanding ability.
  • Exclusion Criteria:
  • 1.A history of drug dependence or alcohol addiction; 2.Serious central system diseases or other systemic diseases such as cardiovascular and cerebrovascular diseases; 3. Patients with organic diseases such as craniocerebral trauma; 4. Sudden deafness, Meniere's disease, otosclerosis, acoustic neuroma and other inner ear or auditory nerve diseases; 5.External otitis, acute/chronic otitis media and other external ear middle-ear related diseases; 6. Patients with auditory hypersensitivity; 7. Pregnancy, preparation for pregnancy, breastfeeding population; 8. There are metal implants in the body, fNIRS detection contraindicated.

About The Third Affiliated Hospital Of Zhejiang Chinese Medical University

The Third Affiliated Hospital of Zhejiang Chinese Medical University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. With a strong focus on patient-centered care, the hospital integrates advanced medical practices with comprehensive educational programs. As a prominent sponsor of clinical trials, it aims to contribute to the development of new therapies and treatment protocols, fostering collaboration among researchers, healthcare professionals, and academic institutions. The hospital's commitment to rigorous scientific inquiry and ethical standards ensures the integrity and reliability of its clinical research initiatives.

Locations

Hangzhou, , China

Patients applied

0 patients applied

Trial Officials

Jie Zhou, M.D

Principal Investigator

The Third Affiliated hospital of Zhejiang Chinese Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported